vs
AVINO SILVER & GOLD MINES LTD（ASM）与RECURSION PHARMACEUTICALS, INC.（RXRX）财务数据对比。点击上方公司名可切换其他公司
RECURSION PHARMACEUTICALS, INC.的季度营收约是AVINO SILVER & GOLD MINES LTD的1.7倍（$35.5M vs $21.0M），AVINO SILVER & GOLD MINES LTD净利率更高（36.6% vs -304.2%，领先340.8%），RECURSION PHARMACEUTICALS, INC.同比增速更快（681.7% vs 44.0%），过去两年RECURSION PHARMACEUTICALS, INC.的营收复合增速更高（60.5% vs 51.1%）
阿维诺金银矿业有限公司是一家加拿大矿业企业，主要从事银、金、铜等贵金属及基本金属的勘探、开发与生产，核心运营资产为位于墨西哥杜兰戈州的旗舰阿维诺矿区，产品供应全球大宗商品市场。
Recursion Pharmaceuticals是一家临床阶段生物技术企业，依托人工智能技术和高通量生物实验体系，开发针对罕见病、肿瘤、炎症性疾病等领域未满足医疗需求的创新疗法，核心市场覆盖北美，与全球多家生物制药企业合作推进在研管线落地。
ASM vs RXRX — 直观对比
营收规模更大
RXRX
是对方的1.7倍
$21.0M
营收增速更快
RXRX
高出637.8%
44.0%
净利率更高
ASM
高出340.8%
-304.2%
两年增速更快
RXRX
近两年复合增速
51.1%
损益表 — Q3 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $21.0M | $35.5M |
| 净利润 | $7.7M | $-108.1M |
| 毛利率 | 47.1% | 59.8% |
| 营业利润率 | — | -304.8% |
| 净利率 | 36.6% | -304.2% |
| 营收同比 | 44.0% | 681.7% |
| 净利润同比 | 558.9% | 39.6% |
| 每股收益（稀释后） | $0.05 | $-0.17 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ASMRXRX
| Q4 25 | — | $35.5M | ||
| Q3 25 | $21.0M | $5.2M | ||
| Q2 25 | $21.8M | $19.2M | ||
| Q1 25 | $18.8M | $14.7M | ||
| Q4 24 | — | $4.5M | ||
| Q3 24 | $14.6M | $26.1M | ||
| Q2 24 | $14.8M | $14.4M | ||
| Q1 24 | $12.4M | $13.8M |
净利润ASMRXRX
| Q4 25 | — | $-108.1M | ||
| Q3 25 | $7.7M | $-162.3M | ||
| Q2 25 | $2.9M | $-171.9M | ||
| Q1 25 | $5.6M | $-202.5M | ||
| Q4 24 | — | $-178.9M | ||
| Q3 24 | $1.2M | $-95.8M | ||
| Q2 24 | $1.2M | $-97.5M | ||
| Q1 24 | $599.0K | $-91.4M |
毛利率ASMRXRX
| Q4 25 | — | 59.8% | ||
| Q3 25 | 47.1% | -183.8% | ||
| Q2 25 | 46.9% | -4.9% | ||
| Q1 25 | 56.1% | -48.0% | ||
| Q4 24 | — | -181.4% | ||
| Q3 24 | 39.1% | 53.7% | ||
| Q2 24 | 31.8% | 36.2% | ||
| Q1 24 | 18.9% | 19.1% |
营业利润率ASMRXRX
| Q4 25 | — | -304.8% | ||
| Q3 25 | — | -3327.6% | ||
| Q2 25 | — | -916.8% | ||
| Q1 25 | — | -1297.9% | ||
| Q4 24 | — | -4042.4% | ||
| Q3 24 | — | -377.1% | ||
| Q2 24 | — | -697.4% | ||
| Q1 24 | — | -698.4% |
净利率ASMRXRX
| Q4 25 | — | -304.2% | ||
| Q3 25 | 36.6% | -3135.3% | ||
| Q2 25 | 13.1% | -894.2% | ||
| Q1 25 | 29.8% | -1373.3% | ||
| Q4 24 | — | -3935.5% | ||
| Q3 24 | 8.0% | -367.5% | ||
| Q2 24 | 8.4% | -676.6% | ||
| Q1 24 | 4.8% | -662.4% |
每股收益（稀释后）ASMRXRX
| Q4 25 | — | $-0.17 | ||
| Q3 25 | $0.05 | $-0.36 | ||
| Q2 25 | $0.02 | $-0.41 | ||
| Q1 25 | $0.04 | $-0.50 | ||
| Q4 24 | — | $-0.56 | ||
| Q3 24 | $0.01 | $-0.34 | ||
| Q2 24 | $0.01 | $-0.40 | ||
| Q1 24 | $0.00 | $-0.39 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $57.3M | $743.3M |
| 总债务越低越好 | — | $9.6M |
| 股东权益账面价值 | $182.1M | $1.1B |
| 总资产 | $221.9M | $1.5B |
| 负债/权益比越低杠杆越低 | — | 0.01× |
8季度趋势，按日历期对齐
现金及短期投资ASMRXRX
| Q4 25 | — | $743.3M | ||
| Q3 25 | $57.3M | $659.8M | ||
| Q2 25 | $37.3M | $525.1M | ||
| Q1 25 | $26.6M | $500.5M | ||
| Q4 24 | — | $594.4M | ||
| Q3 24 | $7.8M | $427.6M | ||
| Q2 24 | $5.3M | $474.3M | ||
| Q1 24 | $3.5M | $296.3M |
总债务ASMRXRX
| Q4 25 | — | $9.6M | ||
| Q3 25 | — | $11.9M | ||
| Q2 25 | — | $14.2M | ||
| Q1 25 | — | $16.4M | ||
| Q4 24 | — | $19.0M | ||
| Q3 24 | — | $20.5M | ||
| Q2 24 | — | $22.9M | ||
| Q1 24 | — | — |
股东权益ASMRXRX
| Q4 25 | — | $1.1B | ||
| Q3 25 | $182.1M | $1.0B | ||
| Q2 25 | $144.8M | $919.1M | ||
| Q1 25 | $132.3M | $933.9M | ||
| Q4 24 | — | $1.0B | ||
| Q3 24 | $114.5M | $524.6M | ||
| Q2 24 | $112.2M | $584.4M | ||
| Q1 24 | $107.8M | $401.2M |
总资产ASMRXRX
| Q4 25 | — | $1.5B | ||
| Q3 25 | $221.9M | $1.4B | ||
| Q2 25 | $174.7M | $1.3B | ||
| Q1 25 | $157.7M | $1.3B | ||
| Q4 24 | — | $1.4B | ||
| Q3 24 | $135.4M | $726.5M | ||
| Q2 24 | $133.7M | $775.9M | ||
| Q1 24 | $128.6M | $557.8M |
负债/权益比ASMRXRX
| Q4 25 | — | 0.01× | ||
| Q3 25 | — | 0.01× | ||
| Q2 25 | — | 0.02× | ||
| Q1 25 | — | 0.02× | ||
| Q4 24 | — | 0.02× | ||
| Q3 24 | — | 0.04× | ||
| Q2 24 | — | 0.04× | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $8.3M | $-46.1M |
| 自由现金流经营现金流 - 资本支出 | — | $-47.3M |
| 自由现金流率自由现金流/营收 | — | -133.1% |
| 资本支出强度资本支出/营收 | — | 3.5% |
| 现金转化率经营现金流/净利润 | 1.08× | — |
| 过去12个月自由现金流最近4个季度 | — | $-378.3M |
8季度趋势，按日历期对齐
经营现金流ASMRXRX
| Q4 25 | — | $-46.1M | ||
| Q3 25 | $8.3M | $-117.4M | ||
| Q2 25 | $8.3M | $-76.4M | ||
| Q1 25 | $758.0K | $-132.0M | ||
| Q4 24 | — | $-115.4M | ||
| Q3 24 | $4.1M | $-59.2M | ||
| Q2 24 | $1.1M | $-82.2M | ||
| Q1 24 | $2.3M | $-102.3M |
自由现金流ASMRXRX
| Q4 25 | — | $-47.3M | ||
| Q3 25 | — | $-117.6M | ||
| Q2 25 | — | $-79.6M | ||
| Q1 25 | — | $-133.8M | ||
| Q4 24 | — | $-116.7M | ||
| Q3 24 | — | $-63.8M | ||
| Q2 24 | — | $-83.4M | ||
| Q1 24 | — | $-109.0M |
自由现金流率ASMRXRX
| Q4 25 | — | -133.1% | ||
| Q3 25 | — | -2272.5% | ||
| Q2 25 | — | -413.9% | ||
| Q1 25 | — | -907.4% | ||
| Q4 24 | — | -2567.7% | ||
| Q3 24 | — | -244.6% | ||
| Q2 24 | — | -578.5% | ||
| Q1 24 | — | -789.9% |
资本支出强度ASMRXRX
| Q4 25 | — | 3.5% | ||
| Q3 25 | — | 4.7% | ||
| Q2 25 | — | 16.4% | ||
| Q1 25 | — | 12.4% | ||
| Q4 24 | — | 28.6% | ||
| Q3 24 | — | 17.5% | ||
| Q2 24 | — | 8.2% | ||
| Q1 24 | — | 48.2% |
现金转化率ASMRXRX
| Q4 25 | — | — | ||
| Q3 25 | 1.08× | — | ||
| Q2 25 | 2.92× | — | ||
| Q1 25 | 0.13× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 3.55× | — | ||
| Q2 24 | 0.87× | — | ||
| Q1 24 | 3.92× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
